Elsevier

Journal of Infection

Volume 36, Issue 1, January 1998, Pages 5-15
Journal of Infection

Review article
Bacteriophages show promise as antimicrobial agents

https://doi.org/10.1016/S0163-4453(98)92874-2Get rights and content

The emergence of antibiotic-resistant bacteria has prompted interest in alternatives to conventional drugs. One possible option is to use bacteriophages (phage) as antimicrobial agents. We have conducted a literature review of all Medline citations from 1966–1996 that dealt with the therapeutic use of phage. There were 27 papers from Poland, the Soviet Union, Britain and the U.S.A. The Polish and Soviets administered phage orally, topically or systemically to treat a wide variety of antibiotic-resistant pathogens in both adults and children. Infections included suppurative wound infections, gastroenteritis, sepsis, osteomyelitis, dermatitis, empyemas and pneumonia: pathogens included Staphylococcus, Streptococcus, Klebsiella, Escherichia, Proteus, Pseudomonas, Shigella and Salmonella spp. Overall, the Polish and Soviets reported success rates of 80–95% for phage therapy, with rare, reversible gastrointestinal or allergic side effects. However, efficacy of phage was determined almost exclusively by qualitative clinical assessment of patients, and details of dosages and clinical criteria were very sketchy. There were also six British reports describing controlled trials of phage in animal models (mice, guinea pigs and livestock), measuring survival rates and other objective criteria. All of the British studies raised phage against specific pathogens then used to create experimental infections. Demonstrable efficacy against Escherichia, Acinetobacter, Pseudomonas and Staphylococcus spp. was noted in these model systems. Two U.S. papers dealt with improving the bioavailability of phage. Phage is sequestered in the spleen and removed from circulation. This can be overcome by serial passage of phage through mice to isolate mutants that resist sequestration. In conclusion, bacteriophages may show promise for treating antibiotic resistant pathogens. To facilitate further progress, directions for future research are discussed and a directory of authors from the reviewed papers is provided.

References (62)

  • JerniganDB et al.

    Minimizing the impact of drug-resistant streptococcus pneumoniae (DRSP): a strategy from the DRSP working group

    JAMA

    (1996)
  • ChopraI et al.

    New approaches to the control of infections caused by antibiotic-resistant bacteria: an industry perspective

    JAMA

    (1996)
  • PlouffeJF et al.

    Bacteremia with streptococcus pneumonia: implications for therapy and prevention

    JAMA

    (1996)
  • RahmanMA et al.

    Antibacterial activity and inhibition of protein synthesis in Escherichia coli by antisense DNA analogs

    Antisense Res Devel

    (1991)
  • TopleyWWC et al.

    The Principles of Bacteriology and Immunity

  • AdamsMH

    Bacteriophages

  • BrockTD

    Milestones in Microbiology

  • Raiga-ClemenceauA

    Le bacteriophage de d'Herelle et son pouvoir therapeutic

    Semaine des Hopitaux Therapeutique

    (1974)
  • DixonB

    Bacteriophage therapy

    B M J Clinical Research Ed

    (1987)
  • KaczkowskiH et al.

    Zastosowanie bakteriofagow w leczeniu przewleklych chorob bakteryjnych

    Wiadomosci Lekarskie

    (1990)
  • SlopekS et al.

    Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evaluation of the results

    Archivum Immunologi˦ et Therapi˦ Experimentalis

    (1983)
  • SlopekS et al.

    Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in further 150 cases

    Archivum Immunologi˦ et Therapi˦ Experimentalis

    (1984)
  • SlopekS et al.

    Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of the results obtained in 370 cases

    Archivum Immunologi˦ et Therapi˦ae Experimentalis

    (1985)
  • SlopekS et al.

    Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections

    Archivum Immunologi˦ et Therapi˦ Experimentalis

    (1985)
  • SlopekS et al.

    Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections

    Archivum Immunologi˦ et Therapi˦ Experimentalis

    (1985)
  • SlopekS et al.

    Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986

    Archivum Immunologi˦ et Therapi˦ Experimentalis

    (1987)
  • CisloM et al.

    Bacteriophage treatment of suppurative skin infections

    Archivum Immunologi˦ et Therapi˦ Experimentalis

    (1987)
  • Weber-DabrowskaB et al.

    Studies on bacteriophage penetration in patients subjected to phage therapy

    Archivum Immunologi˦ et Therapi˦ Experimentalis

    (1987)
  • Kucharewicz-KrukowskaA et al.

    Immunogenic effect of bacteriophage in patients subjected to phage therapy

    Archivum Immunologi˦ et Therapi˦ Experimentalis

    (1987)
  • ChernomordikAB

    Bakteriofagi i ikh lechebno-profilakticheskoe primenenie

    Meditsinskaia Sestra

    (1989)
  • SakandelidzeVM et al.

    Primenenie kombinirovannykh fagov pri gniono-vospalitel'nykh zabolevaniiakh

    Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii

    (1974)
  • Cited by (254)

    • Nanoencapsulation techniques for antimicrobial developments

      2023, Antimicrobial Nanosystems: Fabrication and Development
    • Polymeric and metal nanostructures for bone regeneration and osteomyelitis treatment

      2022, Advances in Nanotechnology-Based Drug Delivery Systems
    • Antibiotic resistance in agriculture: Perspectives on upcoming strategies to overcome upsurge in resistance

      2021, Current Research in Microbial Sciences
      Citation Excerpt :

      But, looking at its immense advantages, it is slowly picking up pace as a new mode of therapy to overcome antibiotic resistance. Bacteriophage therapy has proved to be an excellent alternative against many bacteria (Alisky et al., 1998). Studies have shown that bacteriophages could be used as a good scheme to treat systemic, mucosal and cutaneous infections, and they have also been suggested to be effective against multi-drug resistant bacteria.

    • New Phage cocktail against infantile Sepsis bacteria

      2020, Microbial Pathogenesis
      Citation Excerpt :

      Phage therapy is using lytic phages (virulent phages) as an antibacterial agent for the treatment of bacterial infections and was introduced in such field more than 80 years ago [6]. Phage therapy is a well-known and efficient method of therapy for bacterial infection in many countries world-wide as countries of former Soviet Union and Eastern Europe [6–9]. The emergence of global problem of drug resistance of bacterial pathogens returned the global attention towards phage therapy as a promising alternative therapy against drug-resistant bacterial pathogens [6,7,10,11].

    View all citing articles on Scopus
    View full text